US 11,865,175 B1
Post-transplantation prophylaxis and treatments for antibody-mediated rejection of solid organ transplant
Stanley Jordan, Manhattan Beach, CA (US); Ashley Vo, Northridge, CA (US); and Jua Choi, Porter Ranch, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed on Apr. 30, 2018, as Appl. No. 15/967,034.
Claims priority of provisional application 62/491,498, filed on Apr. 28, 2017.
Int. Cl. A61K 39/395 (2006.01); A61P 37/06 (2006.01); C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39541 (2013.01) [A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61P 37/06 (2018.01); C07K 14/705 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2300/00 (2013.01)] 20 Claims
 
1. A method for post transplant treatment or inhibition of antibody-mediated rejection (ABMR) in a subject who has received an organ transplantation, the method consisting of:
administering a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent in one or more pharmaceutical compositions to the subject who has received an organ transplantation, or
administering a therapeutically effective amount of the IVIG, the anti-CD20 agent, and one or more of antithymocyte globulin, alemtuzumab, a glucocorticoid, mycophenolate mofetil, tacrolimus, and antibiotics, in one or more pharmaceutical compositions to the subject who has received the organ transplantation,
wherein the anti-CD20 agent comprises rituximab, ofatumumab, obinutuzumab, tositumomab, ocaratuzumab, ocrelizumab, TRU-015, IMMU-106, or a combination thereof; and
wherein, if the subject did not receive rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation, or the IVIG is administered only between 7 days and 14 days after the transplantation and the anti-CD20 agent is administered only between 14 days and 21 days after the transplantation, or
wherein, if the subject received the rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation.